ArticleFrontiers in pharmacology2026
Anti-inflammatory effects of 3PO in asthmatic airway inflammation: an integrated study using network pharmacology, molecular modelling, and
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycolytic reprogramming and cell-specific lactylation in asthma: an evidence-graded framework for testable metabolic-epigenetic profiles.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recent studies have highlighted the critical role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) in inflammation, with inhibitors like 3PO showing therapeutic potential in various inflammatory diseases. However, its effect on asthma inflammation remains unclear. Methods: Our study employed an integrative strategy-combining network pharmacology, molecular docking, molecular dynamics simulations, and Results: Firstly, the construction of a protein-protein interaction (PPI) network identified nine hub genes: TNF, IL6, BCL2, IL1B, CASP3, RELA, MAPT, MAOB, and MAOA. Then, the KEGG pathway enrichment analysis identified the nuclear factor kappa B (NF-κB) pathway as a pivotal target. Molecular docking and dynamics simulations suggested stable interactions between 3PO and key inflammatory markers, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and NF-κB P65. For experimental validation, the OVA-induced asthma mouse models were established. PFKFB3 expression was markedly upregulated in the lung tissues of asthmatic mice. 3PO treatment modulated mediator levels in BALF of asthmatic mice by reducing interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), interleukin-17A (IL-17A), IL-1β, TNF-α, IL-6, lactate, Immunoglobulin E (IgE), and chemokine (C-C motif) ligand 11 (CCL11), while elevating interleukin-10 (IL-10). 3PO treatment alleviated hallmark features of asthma in this model, such as airway mucus hypersecretion, goblet cell hyperplasia, and peribronchial infiltration of inflammatory cells, particularly eosinophils. Furthermore, 3PO treatment reversed key protein changes in lung tissue by increasing inhibitor of nuclear factor Kappa B-α(IKB-α) and decreasing p-NF-κB P65. Discussion: These results indicate that 3PO exerts anti-inflammatory effects in asthma, and this process is associated with the suppression of the NF-κB pathway, providing a novel therapeutic rationale for asthma therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.